• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

rAAV-SLC 载体介导的抗肿瘤作用和增加的 Tregs 浸润。

The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector.

出版信息

Mol Biol Rep. 2013 Oct;40(10):5615-23. doi: 10.1007/s11033-013-2663-7.

DOI:10.1007/s11033-013-2663-7
PMID:24078089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3824217/
Abstract

To explore the anti-tumor effect and immune mechanism mediated by a new recombinant adeno-associated virus (rAAV) encoding secondary lymphoid tissue chemokine (SLC) mature peptide gene. AAV Helper-Free system was used for rAAV-SLC package. The anti-tumor effect of SLC was detected by bearing tumor established from Hepal-6 cells both in C57BL/6J and nude mice. Flow cytometry analysis and IHC for Tumor-infiltrating T cells and CD11c+DCs were also investigated to explore the immunological mechanism. rAAV-SLC was successfully packaged in AAV293 cells and transfected Hepal-6 tumor cells at high efficiency. The anti-tumor effect was demonstrated by less tumor weight and longer survival outcome. Coincident with the anti-tumor response, local elaboration of SLC within the tumor bed elicited a heavy infiltration of CD4+, CD8+T cells and CD11c+ dendritic cells into the tumor sites. More importantly, there was higher infiltration of Foxp3+ regulatory T cells (Tregs). Local elaboration of SLC mediated by rAAV-SLC has strong T cell mediated anti-tumor effect. The study also suggested that Tregs in the tumor microenvironment tampered the anti-tumor effect.

摘要

探索新型重组腺相关病毒(rAAV)编码二级淋巴组织趋化因子(SLC)成熟肽基因介导的抗肿瘤作用和免疫机制。采用 AAV 无辅助系统包装 rAAV-SLC。通过在 C57BL/6J 和裸鼠中建立来自 Hepal-6 细胞的肿瘤,检测 SLC 的抗肿瘤作用。还通过流式细胞术分析和肿瘤浸润 T 细胞和 CD11c+DCs 的 IHC 来探讨免疫机制。rAAV-SLC 在 AAV293 细胞中成功包装,并高效转染 Hepal-6 肿瘤细胞。通过肿瘤重量减轻和生存时间延长证明了抗肿瘤作用。与抗肿瘤反应一致,肿瘤床内 SLC 的局部表达引起 CD4+、CD8+T 细胞和 CD11c+树突状细胞大量浸润到肿瘤部位。更重要的是,Foxp3+调节性 T 细胞(Tregs)的浸润水平更高。rAAV-SLC 介导的 SLC 局部表达具有强大的 T 细胞介导的抗肿瘤作用。该研究还表明,肿瘤微环境中的 Tregs 干扰了抗肿瘤作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/9f08abe48ae7/11033_2013_2663_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/00e69d0b9440/11033_2013_2663_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/7675912b7273/11033_2013_2663_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/6ce6502d4c48/11033_2013_2663_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/9f08abe48ae7/11033_2013_2663_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/00e69d0b9440/11033_2013_2663_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/7675912b7273/11033_2013_2663_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/6ce6502d4c48/11033_2013_2663_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7946/3824217/9f08abe48ae7/11033_2013_2663_Fig4_HTML.jpg

相似文献

1
The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector.rAAV-SLC 载体介导的抗肿瘤作用和增加的 Tregs 浸润。
Mol Biol Rep. 2013 Oct;40(10):5615-23. doi: 10.1007/s11033-013-2663-7.
2
Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.由腺相关病毒在肿瘤床局部递送的次级淋巴组织趋化因子的表达可刺激强大的抗肝肿瘤免疫反应。
J Virol. 2007 Sep;81(17):9502-11. doi: 10.1128/JVI.00208-07. Epub 2007 Jun 13.
3
Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.SLC 给药联合 Tregs 耗竭是靶向肝细胞癌的一种有吸引力的策略。
Mol Cancer. 2013 Dec 5;12(1):153. doi: 10.1186/1476-4598-12-153.
4
Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity.耗竭 CD4+ CD25+ 调节性 T 细胞可促进 CCL21 介导的抗肿瘤免疫。
PLoS One. 2013 Sep 2;8(9):e73952. doi: 10.1371/journal.pone.0073952. eCollection 2013.
5
Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.局部递送表达二级淋巴组织趋化因子(SLC)的重组痘苗病毒可导致CD4 T细胞依赖性抗肿瘤反应。
Vaccine. 2004 Jul 29;22(21-22):2894-903. doi: 10.1016/j.vaccine.2003.12.021.
6
Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms.小鼠趋化因子6Ckine/SLC通过血管生成抑制和免疫机制发挥抗肿瘤作用。
J Immunol. 2000 Aug 15;165(4):1992-2000. doi: 10.4049/jimmunol.165.4.1992.
7
Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro.用次级淋巴组织趋化因子和/或白细胞介素-2基因转染的树突状细胞增强了人膀胱肿瘤细胞S中T淋巴细胞的体外细胞毒性。
Cancer Invest. 2009 Nov;27(9):909-17. doi: 10.3109/07357900802375746.
8
T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.由二级淋巴组织趋化因子介导的T细胞依赖性抗肿瘤免疫:增强基于树突状细胞的免疫疗法。
Cancer Res. 2001 Mar 1;61(5):2062-70.
9
More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC.不止趋化作用:一种经rAAV2-SLC修饰的新型抗肿瘤树突状细胞疫苗
Mol Immunol. 2007 Jul;44(15):3797-804. doi: 10.1016/j.molimm.2007.03.026. Epub 2007 May 22.
10
Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.二级淋巴组织趋化因子在体内介导T细胞依赖性抗肿瘤反应。
J Immunol. 2000 May 1;164(9):4558-63. doi: 10.4049/jimmunol.164.9.4558.

引用本文的文献

1
Subtumoral analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle properties.肿瘤下分析表明,基于细胞和粒子特性,PRINT 纳米颗粒的分布存在靶向差异。
Nanomedicine. 2016 May;12(4):1053-1062. doi: 10.1016/j.nano.2015.12.382. Epub 2016 Jan 7.
2
Adeno-associated virus-mediated cancer gene therapy: current status.腺相关病毒介导的癌症基因治疗:现状
Cancer Lett. 2015 Jan 28;356(2 Pt B):347-56. doi: 10.1016/j.canlet.2014.10.045. Epub 2014 Nov 10.

本文引用的文献

1
Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061.支柱文章:转录因子Foxp3对调节性T细胞发育的控制。《科学》2003年。299卷:1057 - 1061页。
J Immunol. 2017 Feb 1;198(3):981-985.
2
Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.调节性T细胞通过在肿瘤部位抑制CD4辅助性T细胞来阻止CD8 T细胞成熟。
J Immunol. 2007 Oct 15;179(8):4969-78. doi: 10.4049/jimmunol.179.8.4969.
3
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
肺内给予CCL21基因修饰的树突状细胞可减轻自发性小鼠支气管肺泡细胞癌的肿瘤负担。
Cancer Res. 2006 Mar 15;66(6):3205-13. doi: 10.1158/0008-5472.CAN-05-3619.
4
CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes.CCR7对于树突状细胞从肠固有层迁移至肠系膜淋巴结至关重要。
J Immunol. 2006 Jan 15;176(2):803-10. doi: 10.4049/jimmunol.176.2.803.
5
Long-term modifications of blood pressure in normotensive and spontaneously hypertensive rats by gene delivery of rAAV-mediated cytochrome P450 arachidonic acid hydroxylase.通过重组腺相关病毒介导的细胞色素P450花生四烯酸羟化酶基因递送对正常血压和自发性高血压大鼠血压的长期调节
Cell Res. 2005 Sep;15(9):717-24. doi: 10.1038/sj.cr.7290341.
6
Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.以CCL21作为佐剂的抗TRP2 DNA黑色素瘤疫苗增强免疫力。
Mol Ther. 2006 Jan;13(1):194-202. doi: 10.1016/j.ymthe.2005.05.018. Epub 2005 Aug 22.
7
The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells.淋巴细胞趋化因子CCL21共刺激初始T细胞扩增以及非调节性CD4+ T细胞的Th1极化。
Cell Immunol. 2004 Sep-Oct;231(1-2):75-84. doi: 10.1016/j.cellimm.2004.12.006. Epub 2005 Jan 21.
8
Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts.腺相关病毒载体在缺血性小鼠心脏中实现心脏特异性和缺氧诱导的血管内皮生长因子表达。
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16280-5. doi: 10.1073/pnas.0407449101. Epub 2004 Nov 8.
9
Regulatory T cells and mechanisms of immune system control.调节性T细胞与免疫系统的调控机制。
Nat Med. 2004 Aug;10(8):801-5. doi: 10.1038/nm0804-801.
10
Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells.外周耐受的基石:天然存在的CD4+CD25+调节性T细胞。
Trends Immunol. 2004 Jul;25(7):374-80. doi: 10.1016/j.it.2004.04.009.